Application of 3D Bioprinting Technologies to the Management and Treatment of Diabetic Foot Ulcers

Application of 3D Bioprinting Technologies to the Management and Treatment of Diabetic Foot Ulcers
Title:
Application of 3D Bioprinting Technologies to the Management and Treatment of Diabetic Foot Ulcers
Other Titles:
Biomedicines
Publication Date:
21 October 2020
Citation:
Tan, C.T.; Liang, K.; Ngo, Z.H.; Dube, C.T.; Lim, C.Y. Application of 3D Bioprinting Technologies to the Management and Treatment of Diabetic Foot Ulcers. Biomedicines 2020, 8, 441. https://doi.org/10.3390/biomedicines8100441
Abstract:
Diabetes mellitus (DM) is a chronic metabolic disease with increasing prevalence worldwide. Diabetic foot ulcers (DFUs) are a serious complication of DM. It is estimated that 15-25% of DM patients develop DFU at least once in their lifetime. The lack of effective wound dressings and targeted therapy for DFUs often results in prolonged hospitalization and amputations. As the incidence of DM is projected to rise, the demand for specialized DFU wound management will continue to increase. Hence, it is of great interest to improve and develop effective DFU-specific wound dressings and therapies. In the last decade, 3D bioprinting technology has made a great contribution to the healthcare sector, with the development of personalized prosthetics, implants, and bioengineered tissues. In this review, we discuss the challenges faced in DFU wound management and how 3D bioprinting technology can be applied to advance current treatment methods, such as biomanufacturing of composite 3D human skin substitutes for skin grafting and the development of DFU-appropriate wound dressings. Future co-development of 3D bioprinting technologies with novel treatment approaches to mitigate DFU-specific pathophysiological challenges will be key to limiting the healthcare burden associated with the increasing prevalence of DM.
License type:
Attribution 4.0 International (CC BY 4.0)
Funding Info:
This research / project is supported by the Agency for Science, Technology and Research - SERC Programmatic Grant
Grant Reference no. : A18A8b0059

This research / project is supported by the Agency for Science, Technology and Research - IAF-PP Program
Grant Reference no. : H17/01/a0/004
Description:
ISSN:
2227-9059
Files uploaded:

File Size Format Action
biomedicines-08-00441-v2-1.pdf 1.26 MB PDF Open